CRISPR Therapeutics (CRSP) Projected to Post Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect CRISPR Therapeutics to post earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the business earned ($1.43) EPS. The company’s revenue was up 71.6% on a year-over-year basis. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Up 5.5%

Shares of NASDAQ CRSP opened at $37.59 on Tuesday. The company has a market capitalization of $3.25 billion, a PE ratio of -8.60 and a beta of 1.88. The stock’s 50 day moving average price is $38.03 and its 200-day moving average price is $42.64. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $67.88.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several research reports. Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. Needham & Company LLC cut their target price on shares of CRISPR Therapeutics from $84.00 to $81.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group lowered their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, March 21st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $71.75.

Insider Transactions at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.